In Consulting Services

PharmaNet offers a comprehensive range of early- and late-phase consulting services on topics including: international regulatory affairs; scientific and medical affairs; quality; risk management; chemistry, manufacturing and controls; as well as biopharmaceutical investor issues.

Business Plan Services

Technology investors expect a clear, concise business plan showing that you're aware of competitive, legal, regulatory, and manufacturing issues. We can assist you in preparing all the materials you need to make a positive impression: a thorough business plan, an accurate financial forecast, and a compelling investor presentation. Our services include developing timelines and cost estimates to meet financial constraints and milestone goals; due diligence; and in-licensing evaluation.

 

PharmaNet professionals available for consultation on this topic include:

 

Andrew Chang, PhD

Executive Director, PharmaNet Consulting


Joyce Lea Frey-Vasconcells, PhD

Executive Director, PharmaNet Consulting


Gregory M. Hockel, MBA, PhD

Senior Vice President, Regulatory Affairs Worldwide


Mary F. Johnson, PhD

Executive Vice President, Biostatistics

 

Francois Xavier Lacasse, PhD

Director, Drug Development, Scientific and Regulatory Affairs, Anapharm


Stephane Lamouche, MSc, PhD

Project Manager, Drug Development, Scientific and Regulatory Affairs, Anapharm

 

Mike Ryan

Executive Director, Strategic Partnering Services


Duu-Gong Wu, PhD

Executive Director, PharmaNet Consulting

 

PharmaNet Development Group, Inc.504 Carnegie Center, Princeton, NJ 08540Tel 609 951 6800Fax 609 514 0390